Daniela Barros
Described for the first time in the 1940s, lipedema has long been misunderstood, often mistaken for common obesity or lymphedema and frequently treated as a cosmetic issue. This has produced chronic underdiagnosis, stigma, and fragmented care.
But that picture has changed structurally with the recent publication of the Lipedema World Alliance’s first international consensus on the definition and management of lipedema, based on the Delphi method.
Specialists from 19 countries contributed 59 consensus statements covering definition, pathophysiology, diagnosis, impact on quality of life, therapeutic strategies, and future research directions. Rather than offering definitive solutions, the document provides a shared starting point for clinicians, researchers, and policymakers.
“For many years, care and research in lipedema were fragmented, not for lack of interest, but because there was no shared definition. Different physicians spoke about the same disease as if they were distinct entities,” said Philipp Kruppa, MD, corresponding author of the consensus. “This document does not solve everything, but it creates a common language, without which it is not possible to advance research, medical education, or health policy.”
The consensus defines lipedema as a chronic disease, characterized by disproportionate and usually symmetrical accumulation of subcutaneous adipose tissue in the limbs, associated with pain, hypersensitivity, a feeling of heaviness, and functional impact, with typical preservation of the hands and feet.
The document explicitly distinguishes lipedema from obesity, while acknowledging that the two often coexist. That conceptual distinction has direct implications for clinical practice and combating the stigma associated with the disease.
“As long as lipedema is seen only as an aesthetic problem or a consequence of lifestyle, medicine will continue to fail these patients,” Kruppa said. “Recognizing it as a chronic disease shifts the focus from judgment to care.”
Biological Basis and Knowledge Gaps
The consensus summarizes advances in knowledge about lipedema pathophysiology while noting the clear gaps. Accumulated evidence showed that the affected adipose tissue shows structural and functional alterations distinct from those seen in obesity, including adipocyte hypertrophy, increased fibrosis, extracellular matrix remodeling, and changes in microcirculation.
These findings help explain why lipedema tissue responds differently to traditional weight-loss strategies.
“Fibrosis plays a central role in this biological difference. The increase in fibrotic tissue reduces the plasticity of adipose tissue and hinders lipid mobilization. That helps explain why, in lipedema, the affected areas respond worse to classical weight-loss strategies, unlike what happens in common obesity,” said André Murad Faria, MD, PhD, endocrinologist and member of the Brazilian Association for the Study of Obesity and Metabolic Syndrome in Sao Paulo, Brazil.
Inflammation is frequently reported in several studies with inflammatory cell infiltration and altered tissue microenvironments.
However, even the consensus takes a cautious stance: It is not yet clear whether the observed inflammation is a primary cause of the disease or a consequence of adipose tissue expansion and remodeling. “That uncertainty is fundamental,” Kruppa noted. “It reminds us that although we have consistent signs of inflammation, the exact mechanisms are not yet fully elucidated, which limits the development of targeted treatments,” he added.
The hereditary component is often observed in lipedema. A family history of the disease is frequently observed in patients with lipedema, with prevalence ranging from 30% to 90% in different studies, suggesting that genetic factors play a relevant role.
“It is essential to maintain increased attention in women with a suggestive family history and in those who report onset or worsening of symptoms during periods of hormonal transition, such as puberty, pregnancy, or menopause,” said Faria. This recurring clinical finding reinforces the need for vigilance in specific groups, he said.
The proposed models include autosomal dominant inheritance with sex limitation or oligogenic models, but specific genetic determinants remain poorly defined. This explains why lipedema still lacks objective diagnostic markers.
Lipedema affects women and often appears or worsens during hormonal transition periods. Alterations in the local estrogen response in the lipedema adipose tissue reinforce the idea that it is biologically distinct from obesity.
“That does not mean treating lipedema with hormones but understanding that the hormonal axis acts as a disease modulator, something that traditionally is not part of the classic approach to obesity,” Faria explained.
Recent studies show that although the affected tissue is relatively resistant, moderate weight loss can reduce absolute volume and symptoms but without correcting the characteristic body disproportionality.
“Weight loss can bring important metabolic and symptomatic benefits, but the disproportionality persists. Therefore, it is essential to align expectations and avoid frustration,” Faria added. Treating concomitant obesity is advisable with well-defined goals.
Clinical Diagnosis, Functional Impact, and Access Challenges
The consensus emphasizes that the diagnosis of lipedema remains clinical, based on detailed history, physical examination, and exclusion of differential diagnoses. No officially approved laboratory, genetic, or imaging tests exist to confirm the disease. Lack of objective tests has historically delayed diagnosis, which in turn is associated with greater symptom burden, worse quality of life, and increased costs for patients and healthcare systems.
Nayara Cioffi Batagini, MD, PhD, a Brazilian specialist in vascular and endovascular surgery who practices at major hospitals including Hospital Sírio-Libanês in Sao Paulo, noted that conceptual standardization will reduce diagnostic variability. “Lipedema has quite characteristic clinical signs, but they were interpreted differently across specialties. The consensus organizes that reasoning and reinforces that tests are complementary, not substitutes for clinical evaluation,” she said.
Current interventions aim to relieve symptoms and prevent or delay progression rather than cure the disease. Conservative strategies, such as compression therapy, tailored exercise, nutritional counseling, and psychological support, are the basis of treatment.
Surgical reduction with lymphatic preservation may be considered for selected patients with progression, persistent pain, or functional limitation despite conservative treatment.
In Brazil, however, translating this knowledge into effective access to care still faces important regulatory barriers. Fábio Kamamoto, surgeon and director of the Instituto Lipedema Brasil in Sao Paulo, said “Even though it is a disease recognized internationally and included in ICD-11 [International Classification of Diseases 11th Revision], lipedema is still not structured within the Sistema Único de Saúde (Brazil’s national public health system that provides universal care) nor properly incorporated into private healthcare.” “The system tends to see surgery as a cost but ignores the cost of not treating disease progression, chronic pain, time away from work, and loss of mobility,” he added.
By acknowledging its own limitations, the consensus highlights the need for longitudinal studies; standardization of diagnostic criteria; development of reproducible assessment instruments; and greater integration between research, clinical practice, and advocacy.
The document frames a delay in the diagnosis of lipedema is a scientific as well as health equity issue.
“This consensus is not the final word,” Kruppa summarized. “It is the foundation from which we can finally build comparable knowledge, train professionals, and discuss public policies in an informed way,” he said.
This story was translated from Medscape’s Portuguese edition.
